AI-generated · cited to primary sources · not investment advice
Beta Drugs Ltd (BETA) May 2025 Filing Analysis
Does management do what it says?
Management has increased the level of in-house API manufacturing for formulations to 80%, up from the previous 70%. (1 exceeded across 1 tracked commitment)
“This will be followed by 20 new molecules in the next 3-5 years.”
Management confirmed that 70% of APIs for formulations are manufactured in-house, maintaining the target level. (2 met across 2 tracked commitments)
“The Company is also looking to further go backward integrating by establishing the new plant for its intermediates. This will help not only to reduce the dependency on China, but will have more reliable and sustainable supply chain for all the KSMs.”
The company expects to receive EU GMP certification and start filing dossiers for the European market within the next year. — target: EU Certificate/Dossier Filing
“So we just have to wait for another one year for this EU certificate.”
See the full cited Management analysis of Beta Drugs Ltd
How durable is the business?
The domestic own brand oncology business has seen significant expansion, surpassing the ₹100 Cr milestone in H1 FY25, driven by new launches and a strong presence in corporate and government hospitals. (4 expanding)
“Domestic own brand Oncology business crossed 100 Cr milestone... Continuous growth with a 5-year CAGR of 30%”
See the full cited Business Model analysis of Beta Drugs Ltd
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.